Sign up for free insights newsletter
Boston Scientific Corp

Boston Scientific Corp

BSXUnited States

Need professional-grade analysis? Visit stockanalysis.com

$68.15
-1.91%
End of day
Market Cap

$102.58B

P/E Ratio

35.63

Employees

59,000

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.67-1.58-1.26-1.47
Calmar-2.43-1.45-0.90-1.47
Sharpe-1.57-1.41-1.06-1.30
Omega0.490.670.790.67
Martin-4.10-3.22-2.55-3.16
Ulcer17.7615.3612.6914.85

Boston Scientific Corp (BSX) Price Performance

Boston Scientific Corp (BSX) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at $68.15, down 1.91% from the previous close.

Over the past year, BSX has traded between a low of $68.15 and a high of $108.14. The stock has lost 33.4% over this period. It is currently 37.0% below its 52-week high.

Boston Scientific Corp has a market capitalization of $102.58B, with a price-to-earnings ratio of 35.63.

About Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$14.24B
EBITDA
$5.34B
Profit Margin
14.44%
EPS (TTM)
1.94
Book Value
16.34

Technical Indicators

52 Week High
$109.50
52 Week Low
$68.03
50 Day MA
$83.02
200 Day MA
$96.60
Beta
0.70

Valuation

Trailing P/E
35.63
Forward P/E
20.00
Price/Sales
5.11
Price/Book
4.23
Enterprise Value
$112.05B